Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Alpha E Integrin

  • Bryan A. AnthonyEmail author
  • Gregg A. Hadley
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_168


Historical Background

CD103 (integrin αEβ7) was first identified through the binding of a monoclonal antibody (HML-1, human mucosal lymphocyte antigne-1) to a population of lymphocytes that is preferentially associated with gut epithelium (Cerf-Bensussan et al. 1987). It was later identified that HML-1 bound to CD103 which was expressed predominantly on CD3+ CD8+ T cells, and the vast majority of these cells were found in the intestinal mucosa (Russell et al. 1994). Several functionally distinct epitopes were identified. The HML-1 and αE7-1 epitopes were found to function as costimulatory molecules in lymphocyte proliferative responses to a breast cancer epithelial cell line while the αE7-2 and αE7-3 epitopes did not provide such costimulation (Russell et al. 1994).

It is now clear that CD103 is a classic integrin heterodimer composed of the β7 and αE integrin (CD103) subunits. As described above, early studies...

This is a preview of subscription content, log in to check access.


  1. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, Brenner MB. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature. 1994;372:190–3.PubMedCrossRefGoogle Scholar
  2. Cerf-Bensussan N, Jarry A, Brousse N, Lisowska-Grospierre B, Guy-Grand D, Griscelli C. A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur J Immunol. 1987;17:1279–85.PubMedCrossRefGoogle Scholar
  3. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64.PubMedPubMedCentralCrossRefGoogle Scholar
  4. del Rio ML, Bernhardt G, Rodriguez-Barbosa JI, Forster R. Development and functional specialization of CD103+ dendritic cells. Immunol Rev. 2010;234:268–81.PubMedCrossRefGoogle Scholar
  5. El-Asady R, Yuan R, Liu K, Wang D, Gress RE, Lucas PJ, Drachenberg CB, Hadley GA. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J Exp Med. 2005;201:1647–57.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Hadley GA, Bartlett ST, Via CS, Rostapshova EA, Moainie S. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. J Immunol. 1997;159:3748–56.PubMedPubMedCentralGoogle Scholar
  7. Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, Debes GF, Lauber J, Frey O, Przybylski GK, Niesner U, de la Rosa M, Schmidt CA, Brauer R, Buer J, Scheffold A, Hamann A. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med. 2004;199:303–13.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL, Berg PL, Davidsson T, Powrie F, Johansson-Lindbom B, Agace WW. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med. 2008;205:2139–49.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Forster R, Agace WW. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005;202:1063–73.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Keino H, Masli S, Sasaki S, Streilein JW, Stein-Streilein J. CD8+ T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance. Invest Ophthalmol Vis Sci. 2006;47:1533–42.PubMedCrossRefGoogle Scholar
  11. Kilshaw PJ, Murant SJ. A new surface antigen on intraepithelial lymphocytes in the intestine. Eur J Immunol. 1990;20:2201–7.PubMedCrossRefGoogle Scholar
  12. Koch SD, Uss E, van Lier RA, ten Berge IJ. Alloantigen-induced regulatory CD8 + CD103+ T cells. Hum Immunol. 2008;69:737–44.PubMedCrossRefGoogle Scholar
  13. Le Floc’h A, Jalil A, Vergnon I, Le Maux CB, Lazar V, Bismuth G, Chouaib S, Mami-Chouaib F. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med. 2007;204:559–70.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, Brunner M, Scheffold A, Hamann A. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci U S A. 2002;99:13031–6.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Robinson PW, Green SJ, Carter C, Coadwell J, Kilshaw PJ. Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103). Immunology. 2001;103:146–54.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Russell GJ, Parker CM, Cepek KL, Mandelbrot DA, Sood A, Mizoguchi E, Ebert EC, Brenner MB, Bhan AK. Distinct structural and functional epitopes of the alpha E beta 7 integrin. Eur J Immunol. 1994;24:2832–41.PubMedCrossRefGoogle Scholar
  17. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRefGoogle Scholar
  18. Wang D, Yuan R, Feng Y, El-Asady R, Farber DL, Gress RE, Lucas PJ, Hadley GA. Regulation of CD103 expression by CD8+ T cells responding to renal allografts. J Immunol. 2004;172:214–21.PubMedCrossRefGoogle Scholar
  19. Yuan R, El-Asady R, Liu K, Wang D, Drachenberg CB, Hadley GA. Critical role for CD103 + CD8+ effectors in promoting tubular injury following allogeneic renal transplantation. J Immunol. 2005;175:2868–79.PubMedCrossRefGoogle Scholar
  20. Zhang L, Moffatt-Bruce SD, Gaughan AA, Wang JJ, Rajab A, Hadley GA. An anti-CD103 immunotoxin promotes long-term survival of pancreatic islet allografts. Am J Transplant. 2009;9:2012–23.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. In vivo-activated CD103 + CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008;112:2129–38.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of SurgeryThe Ohio State University Medical CenterColumbusUSA